ALPHAMAB ONCOLO.DL-000002 (3NK) — Cash Flow-to-Debt Ratio
ALPHAMAB ONCOLO.DL-000002 (3NK) has a Cash Flow-to-Debt Ratio of -0.32x as of December 2025, meaning its operating cash flow of €-121.89 Million could theoretically repay 0% of its total liabilities (€386.17 Million) in one year. See financial agility of ALPHAMAB ONCOLO.DL-000002 to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ALPHAMAB ONCOLO.DL-000002 Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for ALPHAMAB ONCOLO.DL-000002 across 5 annual periods. For the full cash flow conversion analysis, see 3NK cash flow metrics.
Annual Cash Flow-to-Debt Ratio for ALPHAMAB ONCOLO.DL-000002 (2021–2025)
Year-by-year debt coverage analysis for ALPHAMAB ONCOLO.DL-000002. Check ALPHAMAB ONCOLO.DL-000002 earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.32x | €-121.89 Million | €386.17 Million | ▼ -160.9% |
| 2024 | 0.52x | €212.34 Million | €409.87 Million | ▲ +218.8% |
| 2023 | -0.44x | €-202.84 Million | €465.00 Million | ▲ +18.7% |
| 2022 | -0.54x | €-300.31 Million | €559.86 Million | ▼ -39.7% |
| 2021 | -0.38x | €-320.60 Million | €834.80 Million | — |